Head and Neck Cancer

Anus, Breast, Colon, Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Other Digestive Organ, Pancreas, Phase I, Rectum, Small Intestine, Stomach, ThyroidAn Open-label, Phase 1a/b, Multicenter Study of ZL-6201 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Participants With Sarcoma and Selected Solid Tumors
Breast, Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Lung, Other Urinary, Phase I, ThyroidFirst-In-Human, Open-Label, Dose Escalation and Expansion Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of GEN1106 in Participants With Solid Tumors
Lip, Oral Cavity and PharynxA Pilot Study of CUE-101 in Combination With Pembrolizumab in Subjects With Newly Diagnosed, Locally Advanced HPV-16 Associated Head and Neck Cancer
Colon, Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Lung, Other Digestive Organ, Pancreas, Phase I, Rectum, Small Intestine, StomachA Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Anus, Esophagus, Lip, Oral Cavity and Pharynx, Lung, Other Female Genital, Other Male Genital, Other Urinary, Phase I, Urinary BladderA Phase 1 Dose-Escalation and Expansion Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EVOLVE104 in Subjects With Advanced Urothelial and Squamous Cell Carcinomas